COMP <GO>
IOVA vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Iovance Biotherapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: IOVA 3
— JNJ 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: IOVA
LAST: $8.48 (-11.30%) • MKT CAP: $4.33B
options-implied-move
6.90%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
options-implied-move
7.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IOVA VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IOVA | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 34.30% | 67.90% | -33.60 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.76% | 2.97% | -10.73 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 60.60% | 6.00% | +54.60 | IOVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.08 | 5.59 | +1.49 | IOVA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.90% | 7.20% | -0.30 | IOVA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.4 | 60.4 | -29.97 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.08 | -0.09 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 23.0x | +10.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.33B | $662.49B | -$658.16B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IOVA REV | JNJ REV | IOVA GROSS % | JNJ GROSS % | IOVA FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $263.5M | $94.19B | 34.3% | 67.9% | -$336.2M | $19.70B |
| FY 2024 | $164.1M | $88.82B | 43.2% | 69.1% | -$364.0M | $19.84B |
| FY 2023 | $1.2M | $85.16B | 44.0% | 44.0% | -$361.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IOVA // BETA 0.99
JNJ // BETA 1.08